Effects of β-alanine and Sodium Bicarbonate Supplementation on Physical Capacity and Biochemical Markers Concentrations

NCT07092930 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2025-07-30

No results posted yet for this study

Summary

This randomized, double-blind, placebo-controlled, parallel-group study aims to evaluate the potential synergistic effect of beta-alanine (BA) and sodium bicarbonate (SB) supplementation, compared to their separate administration or placebo (PL), on physical performance and selected blood biochemical markers in highly trained female basketball players.

Conditions

  • Supplementation
  • Sports
  • Female Athletes

Interventions

DIETARY_SUPPLEMENT

BA and SB supplementation

Assigned Interventions: * Beta-alanine (BA) * Sodium bicarbonate (SB) Description: • Participants receive beta-alanine and sodium bicarbonate Intervention list \& supplementation details: 1. Beta-alanine (BA) * Form: Gelatin capsules * Substance: Pure beta-alanine * Daily dose: 6.4 g/day * Dosing schedule: Four equal servings taken with meals (breakfast, lunch, snack, dinner) * Supplementation period: days 1 to 28 2. Sodium bicarbonate (SB) * Form: Gelatin capsules * Substance: Pure sodium bicarbonate * Daily dose: 0.3 g/kg body mass per day * Dosing schedule: Three equal servings taken with meals (breakfast, lunch, dinner) * Supplementation period: days 21 to 28 of BA or PL1 supplementation Rationale: • This group tests the combined effects of BA and SB

DIETARY_SUPPLEMENT

BA and PL2 supplementation

Participants in this intervention group will undergo chronic supplementation with beta-alanine (BA) and an inert placebo (PL2) matched to the sodium bicarbonate (SB) protocol. * Beta-alanine (pure, in gelatin capsules) will be administered at a total daily dose of 6.4 g, divided into four servings taken with meals, over a period of 28 consecutive days. * PL2 (placebo matched to SB, in gelatin capsules) will be administered from Day 21 to Day 28 of beta-alanine supplementation, at a daily dose of 0.3 g per kg of body mass, divided into three equal servings taken with meals. This group allows for evaluation of the isolated effects of BA supplementation when combined with a placebo comparator to SB

DIETARY_SUPPLEMENT

PL1 and SB supplementation

Assigned Interventions: * Placebo matched to BA (PL1) * Sodium bicarbonate (SB) Description: • Participants receive only sodium bicarbonate as the active compound and placebo capsules matching the BA protocol. Intervention list \& supplementation details: 1. Placebo matched to BA (PL1) * Form: Gelatin capsules * Substance: Inert substance matched in appearance and dosing schedule to BA * Daily dose: 6.4 g/day * Dosing schedule: Four equal servings taken with meals (breakfast, lunch, snack, dinner) * Supplementation period: days 1 to 28 2. Sodium bicarbonate (SB) * Form: Gelatin capsules * Substance: Pure sodium bicarbonate * Daily dose: 0.3 g/kg body mass per day * Dosing schedule: Three equal servings taken with meals (breakfast, lunch, dinner) * Supplementation period: days 21 to 28 of BA or PL1 supplementation Rationale: • This group tests the isolated effects of SB

DIETARY_SUPPLEMENT

PL1 and PL2 supplementation

Assigned Interventions: * Placebo matched to BA (PL1) * Placebo matched to SB (PL2) Description: • Participants receive two matched placebos. Intervention list \& supplementation details: 1. Placebo matched to BA (PL1) * Form: Gelatin capsules * Substance: Inert substance matched in appearance and dosing schedule to BA * Daily dose: 6.4 g/day * Dosing schedule: Four equal servings taken with meals (breakfast, lunch, snack, dinner) * Supplementation period: days 1 to 28 2. Placebo matched to SB (PL2) * Form: Gelatin capsules * Substance: Inert substance matched in appearance and timing to SB * Daily dose: 0.3 g/kg body mass per day * Dosing schedule: Three equal servings taken with meals (breakfast, lunch, dinner) * Supplementation period: days 21 to 28 of BA or PL1 supplementation Rationale: • This serves as the control group for comparison with all active intervention arms.

Sponsors & Collaborators

  • Poznan University of Physical Education

    lead OTHER

Principal Investigators

  • Krzysztof Durkalec-Michalski, PhD · Department of Sports Dietetics, Poznan University of Physical Education Poznań

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
16 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-10-01
Primary Completion
2025-12-31
Completion
2025-12-31

Countries

  • Poland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07092930 on ClinicalTrials.gov